# Lexeo Therapeutics

Lexeo Therapeutics is an Asset Manager based in New York, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** New York, NY, United States
- **Assets under management:** Undisclosed
- **Website:** lexeotx.com
- **LinkedIn:** https://www.linkedin.com/company/lexeo-therapeutics

## Regulatory record

- **Reports private funds:** No

## About

Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. For more information, please visit www.lexeotx.com.

## Sectors

- Biotech
- Gene Therapy
- Cardiovascular
- Central Nervous System
- Rare Diseases

## People

- Nolan Townsend — Chief Executive Officer
- Eric Adler — Chief Scientific Officer
- Brendan Smith — Chief Financial Officer
- Gaurav Shah — President and Head of R&D

## Questions

### Who makes investment decisions at Lexeo Therapeutics?

Investment decisions at Lexeo are made by its management team under CEO Nolan Townsend and guided by the board of directors. The company operates as a public biotech, so capital allocation is overseen by the CFO and approved by the board. No external family office or single principal controls strategy.

### How does Lexeo source its pipeline programs?

Lexeo's pipeline originates from foundational research at Weill Cornell Medicine and UC San Diego, where the company's scientific founders are based. The firm in-licenses gene therapy candidates from these academic institutions and advances them through clinical development. Lexeo also explores strategic collaborations to expand its pipeline.

### What therapeutic areas does Lexeo focus on?

Lexeo focuses on two primary areas: genetic cardiovascular diseases and APOE4-associated Alzheimer's disease. Its cardiac pipeline includes gene therapies for Friedreich's ataxia cardiomyopathy, arrhythmogenic cardiomyopathy, and hypertrophic cardiomyopathy. Its CNS program targets Alzheimer's disease in APOE4 carriers.

### Where does Lexeo's original technology come from?

Lexeo's gene therapy platform is built on research from Weill Cornell Medicine and the University of California San Diego. Key scientific founders include Dr. Ronald Crystal and Dr. Eric Adler, who continue to collaborate with the company. The firm has licensed intellectual property from these institutions.

### How does Lexeo differentiate from other gene therapy companies?

Lexeo differentiates by focusing exclusively on genetic cardiac disease, a niche with fewer competitors than CNS or oncology gene therapy. The company uses AAV vectors optimized for cardiac delivery and maintains a strong academic partnership model. Its public status provides transparency and access to public markets.

## Related profiles

- [Octagon Capital Group](https://altss.com/profile/octagon-capital-group)
- [Waste Harmonics](https://altss.com/profile/waste-harmonics)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/lexeo-therapeutics

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology